Dermatitis-Ltd Controls Psoriasis

Dermatitis-Ltd will improve the skin beauty, and appearance of many forms of psoriasis. Dermatitis-Ltd provides the latest information concerning the various types of psoriasis along with up to date information on the cause and treatment options for psoriasis.

FDA GIVES THE GREEN LIGHT FOR NEW PSORIASIS TREATMENT

Medicis Pharmaceuticals Inc. Tuesday announced that the Food and Drug Administration (FDA) has approved its new drug application for VANOS, used for the treatment of plaque-type psoriasis.
According to the Scottsdale-based company's announcement, VANOS is a patented corticosteroid formula that when put in the form of a cream helps to relieve plaque-type psoriasis, a skin disorder.
The market for this type of treatment is approximately $329 million annually, officials said.
Medicis anticipates launching VANOS to dermatologists in early April.
VANOS is manufactured by Patheon Inc. in Canada.
Medicis (NYSE: MRX) is an independent specialty pharmaceutical company focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine.
For more: www.medicis.com.

Link Between Mother's Psoriasis and Child's Autism

New Study Finding Increased Autism in Kids Whose Mothers HavePsoriasis Underscores Dramatic Need for More Psoriasis Research
2/7/2005 10:19:00 PM
To: National Desk, Medical Reporter
Contact: Michael Paranzino of Psoriasis Cure Now!, 202-253-4863 or michael@psorcurenow.org
KENSINGTON, Md., Feb. 7 /U.S. Newswire/ -- A new study in the February issue of the Archives of Pediatrics and Adolescent Medicine found a troubling association between a mother's psoriasis and her children's autism. The study, which reviewed more than 88,000 children born between 1995 and 1999, found that only one immune disorder present in the mother, psoriasis, was "significantly associated" with an autism spectrum disorder.

"Psoriasis Cure Now!," a psoriasis patient advocacy group, responded to the troubling new findings. "Given that there are roughly 3 million women of child-bearing age with psoriasis across America, this new study is of great concern to us," said Michael Paranzino, president of "Psoriasis Cure Now!"

"We need Congress to support additional research to study this association further, including to determine if it is the psoriasis, or one or more psoriasis treatments, which may be leading to this increased risk of having a child with autism."

While funding for the National Institutes of Health (NIH) is up 148 percent over the last decade, psoriasis research funding at NIH's skin institute has actually been cut by 13 percent. Today, the federal government spends just $5 million annually, or 77 cents per patient, researching psoriasis and psoriatic arthritis.

"Psoriasis Cure Now!" is calling on Congress to support emergency research to examine several important questions raised by this study, including:

Can these finding be replicated by other researchers?

Which psoriasis treatments have been used by the mothers whose children have autism?

Are certain psoriasis treatments associated with this finding?

Does psoriasis severity play a role in this; i.e., do women with mild psoriasis have the same rate of children with autism as mothers with severe psoriasis?

Do fathers with psoriasis produce a higher rate of children with autism than fathers without psoriasis?

"Expectant mothers with psoriasis already have so much on their minds," Paranzino continued, "in part because psoriasis treatment options for pregnant women are so limited. Parents with psoriasis also have to contend with the fact that their children will be at increased risk to develop psoriasis. We urge women with psoriasis to speak with their physicians about this new study. These women deserve answers."

The letter to Congress can be found here:
http://www.psorcurenow.org/autism.php
http://www.usnewswire.com/